Abstract | BACKGROUND: OBJECTIVE: The objective of this detailed retrospective data review was to characterize anaphylaxis cases within the ecallantide clinical trials database. METHODS: Potential cases of hypersensitivity reactions in the ecallantide clinical development program were identified by examining reported adverse events. The National Institute of Allergy and Infectious Disease criteria were used to identify those events that were consistent with anaphylaxis; these cases were then reviewed in detail. Results from investigational antibody testing also were examined. RESULTS: CONCLUSION:
|
Authors | Timothy J Craig, H Henry Li, Marc Riedl, Jonathan A Bernstein, William R Lumry, Andrew J MacGinnitie, Leslie E Stolz, Joseph Biedenkapp, Yung Chyung |
Journal | The journal of allergy and clinical immunology. In practice
(J Allergy Clin Immunol Pract)
2015 Mar-Apr
Vol. 3
Issue 2
Pg. 206-212.e4
ISSN: 2213-2201 [Electronic] United States |
PMID | 25609335
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Immunoglobulins
- Peptides
- ecallantide
- Kallikreins
|
Topics |
- Adolescent
- Adult
- Aged
- Anaphylaxis
(blood, chemically induced, diagnosis, immunology)
- Angioedemas, Hereditary
(drug therapy)
- Child
- Drug Hypersensitivity
(blood, diagnosis, etiology, immunology)
- Female
- Humans
- Immunoglobulins
(blood)
- Injections, Intravenous
- Injections, Subcutaneous
- Kallikreins
(antagonists & inhibitors)
- Male
- Middle Aged
- Peptides
(administration & dosage, adverse effects, therapeutic use)
- Skin Tests
- Young Adult
|